Form 4: Corcept CEO Sells Shares Under Pre-Arranged 10b5-1 Plan

Corcept Therapeutics CEO Joseph K. Belanoff sold 26,198 shares of common stock for approximately $1.31 million under a pre-arranged 10b5-1 trading plan.

Summary

• Joseph K. Belanoff, CEO, Director, and 10% Owner of Corcept Therapeutics Inc. (CORT), sold 26,198 shares of common stock.
• The transaction occurred on March 25, 2026, at a weighted average sale price of $50.0735 per share.
• The total value of the shares sold was approximately $1,311,730.77.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Belanoff on November 26, 2024.
• Following the transaction, Mr. Belanoff beneficially owns 2,918,326 shares indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-scheduled under a 10b5-1 plan, which typically indicates personal financial planning rather than a reaction to new company-specific information.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 trading plans are a common practice for executives to manage personal finances, diversify holdings, and provide liquidity without implying a negative outlook on the company's future performance. Such pre-scheduled sales typically reduce the immediate negative signal often associated with open market insider sales.

Comparison to Industry Standards

• This Form 4 filing reports an individual insider transaction and does not contain company-specific performance metrics that can be directly compared to industry standards or global benchmarks.

Related Party Transactions

• Joseph K. Belanoff disclaims beneficial ownership of shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, except to the extent of his pecuniary interest therein, while retaining voting power over these shares.

Stakeholder Impact

• Shareholders may perceive a minor, neutral impact as the sale was pre-planned and does not necessarily reflect a change in management's confidence in the company's long-term prospects.

Key Dates

Recommendation

The sale by CEO Joseph K. Belanoff was executed under a pre-arranged 10b5-1 trading plan, indicating a planned diversification or liquidity event rather than a reaction to new material information. This type of transaction is generally considered neutral and does not typically signal a change in the company's fundamental outlook, thus a 'hold' recommendation is appropriate.

Keywords

CORT, Corcept Therapeutics, Joseph K. Belanoff, Insider Sale, Form 4, 10b5-1 Plan, Stock Transaction, CEO